![]() |
市场调查报告书
商品编码
1497651
生技药品市场:按来源、产品、适应症和最终用户划分 - 2024-2030 年全球预测Biologics Market by Source (Mammalian, Microbial), Product (Antisense & RNAi Therapeutics, Monoclonal Antibodies, Recombinant Hormones or Proteins), Indication, End-user - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年生技药品市场规模为4,057.6亿美元,预估2024年将达4,305.9亿美元,2030年将达6,263.4亿美元,复合年增长率为6.39%。
生技药品是生物医学领域不可或缺的一部分,该领域专注于开发、製造和销售源自生物来源的生物治疗药物,以解决各种健康状况。疫苗、基因治疗和单株抗体等产品对于治疗癌症、自体免疫疾病和遗传疾病等严重疾病至关重要。这些治疗对于医学机构和需要创新治疗的患者至关重要。可使用生技药品治疗的慢性疾病盛行率的上升正在推动生技药品市场的成长。医疗基础设施投资的增加和医疗成本的上升正在扩大先进生物製药治疗的获取范围,并为市场成长提供了跳板。高製造成本、生物相似药日益激烈的竞争以及分销所需的物流(尤其是低温运输要求)正在阻碍市场成长。人们越来越倾向于个人化医疗,即根据个人的基因组成提供量身定制的治疗方法,预计将为市场成长创造机会。开拓生物技术公司和学术机构之间的研发合作伙伴关係,以加强与生技药品相关的创新,预计将扩大市场范围。
主要市场统计 | |
---|---|
基准年[2023] | 4057.6亿美元 |
预测年份 [2024] | 4305.9亿美元 |
预测年份 [2030] | 6263.4亿美元 |
复合年增长率(%) | 6.39% |
区域洞察
美洲因其强大的研究框架、大量投资和鼓励创新的健全专利法而成为生技药品市场的重要地区。此外,美国拥有成熟的生技药品市场,并得到支持生物技术进步的医疗保健政策的支持。最近的进展包括 FDA 加速核准罕见疾病的生物治疗方法,这表明政府的大力支持。美洲的主要企业不断进行併购,推动该地区的成长和创新。欧盟 (EU) 对生技药品有严格的监管标准,以确保治疗的高度安全性和有效性。欧盟消费者重视永续且符合道德开发的产品,影响公司采用更环保的技术和实践。欧洲药品管理局(EMA)积极协调成员国,简化生技药品的核准流程,帮助新治疗方法快速进入市场。中东和非洲地区充满活力,海湾国家在医疗基础设施和生技药品方面进行了大量投资。消费者对生物治疗的认识与接受程度不断提高。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在生技药品市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对生技药品市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该领域竞争性质的宝贵见解,包括累积研究期、片段化优势和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在生技药品市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[180 Pages Report] The Biologics Market size was estimated at USD 405.76 billion in 2023 and expected to reach USD 430.59 billion in 2024, at a CAGR 6.39% to reach USD 626.34 billion by 2030.
Biologics are integral to the biomedical sector, focusing on developing, manufacturing, and distributing biological treatments derived from living organisms to combat various health conditions. Products, including vaccines, gene therapies, and monoclonal antibodies, are pivotal in treating serious ailments such as cancer, autoimmune disorders, and genetic diseases. These treatments are crucial in healthcare facilities and also for patients in need of innovative therapies. The rising prevalence of chronic diseases that can be treated with biologics is driving the growth of the biologics market. Increasing investments in healthcare infrastructure and an increase in healthcare spending are widening the accessibility of advanced biologic treatments, creating a platform for market growth. High manufacturing costs, rising competition from biosimilars, and demanding logistics for distribution, particularly cold chain requirements hampers the market growth. A rising inclination toward personalized medicine that provides tailored therapies based on individual genetic makeup is expected to create opportunities for market growth. Growing partnerships in research and development between biotech companies and academic entities to enhance innovation associated with biologics are anticipated to expand the market scope.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 405.76 billion |
Estimated Year [2024] | USD 430.59 billion |
Forecast Year [2030] | USD 626.34 billion |
CAGR (%) | 6.39% |
Regional Insights
The Americas represents a significant region in the biologics market, driven by strong research frameworks, substantial investments, and robust patent laws that encourage innovation. Additionally, America has a well-established biologics market supported by healthcare policies that favor biotechnological advancements. Recent trends include the FDA's accelerated approval of biological treatments for rare diseases, showcasing a significant government endorsement. Key players in the Americas are consistently engaging in mergers and acquisitions, bolstering growth and innovation in this region. The European Union exhibits stringent regulatory standards for biologics, ensuring high safety and efficacy of treatments. Consumers in the EU focus on sustainable and ethically developed products, influencing companies to adopt greener technologies and practices. The European Medicines Agency (EMA) actively coordinates across member states to streamline the approval processes for biologics, fueling rapid market entry of new therapies. The Middle East and Africa region presents a dynamic landscape, with Gulf countries investing heavily in healthcare infrastructure and the biologics sector. There is a growing awareness and acceptance of biological treatments among consumers.
Market Insights
The market dynamics represent an ever-changing landscape of the Biologics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biologics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biologics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Approves First Tocilizumab Biosimilar, TOFIDENCE, Enhancing Access to Treatment for Autoimmune Diseases
Biogen Inc. announced that TOFIDENCE (tocilizumab-bavi), a biosimilar to the monoclonal antibody ACTEMRA, has received U.S. FDA approval for intravenous use in treating moderately to severely active rheumatoid arthritis, as well as polyarticular and systemic juvenile idiopathic arthritis. This marks the first tocilizumab biosimilar cleared in the United States, potentially offering significant cost savings and wider therapy accessibility. The approval is pivotal, considering the annual 10%-25% increase in spending on autoimmune treatments over the last decade. [Published On: 2023-09-29]
Eli Lilly Expands Investment in Irish Biologics Manufacturing Facility
Eli Lilly invested in its biologics production facility, which is currently under construction in Raheen, Limerick County, Ireland. Eli Lilly injected an additional USD 500 million into the site, elevating its total expenditure to approximately 927 million USD 1 billion. [Published On: 2023-03-26]
Sandoz Announces Major Investment in New Biologics Facility in Slovenia
Sandoz invested over USD 400 million to construct a new biologics production facility in Lendava, Slovenia. This strategic development is aimed at bolstering the company's biosimilar portfolio. The construction underscores Sandoz's commitment to expanding its global presence while significantly contributing to local economic growth. [Published On: 2023-03-10]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biologics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Biologics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Biogen Inc., BioPharm Laboratories, LLC, Bristol Myers Squibb Company, Catalent, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Innovent Biologics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Inc..
Market Segmentation & Coverage